Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors

Current Opinion in Immunology

Volumn 33, Issue , 2015, Pages 1-8

  Chester, Cariad ^a   Marabelle, Aurelien ^b   Houot, Roch ^c,d   Kohrt, Holbrook E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CD137 ANTIGEN; CD16 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CD47 ANTIGEN; CD70 ANTIGEN; CETUXIMAB; CYCLOPHOSPHAMIDE; ELOTUZUMAB; GEMTUZUMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIRILUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; NIVOLUMAB; OZOGAMICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; URELUMAB; VARLILUMAB; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; GLIOBLASTOMA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LIVER CANCER; LUNG CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR IMMUNITY; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84920999004     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.12.010     Document Type: Review

References (61)

1. Ziccardi R.J. The first component of human complement (C1): activation and control. Springer Semin Immunopathol 1983, 6:213-230.
2. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009, 9:729-740.
3. Kemper C., Atkinson J.P. T-cell regulation: with complements from innate immunity. Nat Rev Immunol 2007, 7:9-18.
4. Bologna L., Gotti E., Manganini M., Rambaldi A., Intermesoli T., Introna M., Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody. J Immunol 2011, 186:3762-3769.
5. Unkeless J.C. Function and heterogeneity of human fc receptors for immunoglobulin G. J Clin Invest 1989, 83:355-361.
6. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
7. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patient with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796.
8. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
9. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., Chang H.M., Borucka E., Lurje G., Sherrod A.E., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-3718.
10. Lin W., Voskens C.J., Zhang X., Schindler D.G., Wood A., Burch E., Wei Y., Chen L., Tian G., Tamada K., et al. Fc-dependent expression of CD137 on human NK cells: Insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood 2008, 112:699-707.
11. Shuford W.W., Klussman K., Tritchler D.D., Loo D.T., Chalupny J., Siadak A.W., Brown T.J., Emswiler J., Raecho H., Larsen C.P., et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186:47-55.
12. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellstrom K.E., Mittler R.S., Chen L. Monoclonal antibodies against the 4-1BB t-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
13. Vinay D.S., Kwon B.S. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11:1062-1070.
14. Melero I., Johnston J.V., Shufford W.W., Mittler R.S., Chen L. NK1.1 cells express 4-1BB (CDW137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998, 190:167-172.
15. Wilcox R.A., Tamada K., Strome S.E., Chen L. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 2002, 169:4230-4236.
16. Kohrt H.E., Houot R., Goldstein M.J., Weiskopf K., Alizadeh A.A., Brody J., Muller A., Pachynski R., Czerwinski D., Coutre S., et al. CD137 stimulation enhances the antilymphoma activity of anti-cd20 antibodies. Blood 2011, 117:2423-2432.
17. Kohrt H.E., Houot R., Weiskopf K., Goldstein M.J., Scheeren F., Czerwinski D., Colevas A.D., Weng W.K., Clarke M.F., Carlson R.W., et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122:1066-1075.
18. Kohrt H.E., Colevas A.D., Houot R., Weiskopf K., Goldstein M.J., Lund P., Mueller A., Sagiv-Barfi I., Marabelle A., Lira R., et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014, 124:2668-2682.
19. Lens S.M., Tesselaar K., van Oers M.H., van Lier R.A. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998, 10:491-499.
20. Hendriks J., Gravestein L.A., Tesselaar K., van Lier R.A., Schumacher T.N., Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000, 1:433-440.
21. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., Smyth M.J. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002, 3:83-90.
22. Vitale L.A., He L.Z., Thomas L.J., Widger J., Weidlick J., Crocker A., O'Neill T., Storey J., Glennie M.J., Grote D.M., et al. Development of a human monoclonal antibody for potential therapy of CD-27 expressing lymphoma and leukemia. Clin Cancer Res 2012, 18:3812-3821.
23. He L.Z., Prostak N., Thomas L.J., Vitale L., Weidlick J., Crocker A., Pilsmaker C.D., Round S.M., Tutt A., Glennie M.J., et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor. J Immunol 2013, 191:4174-4183.
24. Thomas L.J., He L.Z., Marsh H., Keler T. Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology 2014, 3:e27255. doi: 2013/oncoimm/0327.
25. Infante R. Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. ASCO 2014 Poster Presentation 2014, http://meetinglibrary.asco.org/content/94952?media=vm.
26. Eliopoulos A.G., Young L.S. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004, 4:360-367.
27. Vonderheide R.H., Glennie M.J. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013, 19:1035-1043.
28. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma. Science 2011, 331:1612-1616.
29. Hassan S.B., Sorensen J.F., Olsen B.N., Pedersen A.E. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical. Immunopharmacol Immunotoxicol 2014, 36:96-104.
30. de Vos S., Forero-Torres A., Ansell S.M., Kahl B., Cheson B.D., Barlett N.L., Furman R.R., Winter J.N., Kaplan H., Timmerman J., et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large. J Hematol Oncol 2014, 7:44.
31. Fanale M., Assouline S., Kuruvilla J., Solal-Celigny P., Heo D.S., Verhoef G., Corradini P., Abramson J.S., Offner F., Engert A., et al. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 2014, 164:258-265.
32. Placke T., Kopp H.G., Salih H.R. Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor. Clin Dev Immunol 2010, 2010:e239083. 10.1155/2010/239083.
33. Cohen A.D., Schaer D.A., Liu C., Yanyun L., Hirschhorn-Cymmerman D., Kim S.C., Diab A., Rizzuto G., Duan F., Perales M.A., et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010, 5. e10436/.
34. Ko K., Yamazaki S., Nakamura K., Nishioka T., Hirota K., Yamaguchi T., Shimizu J., Nomura T., Chiba T., Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005, 202:885-891.
35. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004, 200:771-782.
36. Baltz K.M., Krusch M., Baessler T., Schmiedel B.J., Bringmann A., Brossart P., Salih H.R. Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood 2008, 112:3735-3743.
37. Liu B., Li Z., Mahesh S.P., Pantanelli S., Hwang F.S., Siu W.O., Nussenblatt R.B. Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis. J Biol Chem 2008, 283:8202-8210.
38. Buechele C., Baessler T., Wirths S., Schmohl J.U., Schmiedel B.J., Salih H.R. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 2012, 26:991-1000.
39. Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I., Kroczek R.A. ICOS is an inducible t-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
40. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2:116-126.
41. McAdam A.J., Chang T.T., Lumelsky A.E., Greenfield E.A., Boussiotis V.A., Duke-Cohan J.S., Chernova T., Malenkovich N., Jabs C., Kuchroo V.K., et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000, 165:5035-5040.
42. Liakou C.I., Kamat A., Tang D.N., Chen H., Sun J., Troncose P., Logothetis C., Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008, 105:14987-14992.
43. Carthon B.C., Wolchok J.D., Yuan J., Kamat A., Ng Tang D.S., Sun J., Ku G., Troncoso P., Logothetis C.J., Allison J.P., Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010, 16:2861-2871.
44. Ogasawara K., Yoshinaga S.K., Lanier L.L. Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in activated murine NK cells. J Immunol 2002, 169:3676-3685.
45. Fan X., Quezada S.A., Sepulveda M.A., Sharma P., Allison J.P. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014, 211:715-725.
46. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002, 20:217-251.
47. Koh C.Y., Blazar B.R., George T., Welniak L.A., Capitini C.M., Raziuddin A., Murphy W.J., Bennett M. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001, 97:3132-3137.
48. Romagne F., Andre P., Spee P., Zahn S., Anfossi N., Gauthier L., Capanni M., Ruggeri L., Benson D.M., Blaser B.W., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114:2667-2677.
49. Terszowski G., Klein C., Stern M. KIR/HLA interactions negatively affect rituximab-but not GA101 (obinutuzumab)-induced antibody dependent cellular cytotoxicity. J Immunol 2014, 192:5618-5624.
50. Kohrt H.E., Thielens A., Marabelle A., Sagiv-Barfi I., Sola C., Chanuc F., Fuseri N., Bonnafous C., Czerwinski D., Rajapaksa A., et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014, 123:678-686.
51. Jaiswal S., Chao M.P., Majeti R., Weissman I.L. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010, 31:212-219.
52. Oldenborg P.A., Zheleznyak A., Fang Y.F., Lagenaur C.F., Gresham H.D., Lindberg F.P. Role of CD47 as a marker of self on red blood cells. Science 2000, 288:2051-2054.
53. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., van Rooijen N., Weissman I.L. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
54. Willingham S.B., Volkmer J.P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., Wang J., Contreras-Trujillo H., Martin R., Cohen J.D., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012, 109:6662-6667.
55. Tseng D., Volkmer J.P., Willingham S.B., Contreras-Trujillo H., Fathman J.W., Fernhoff N.B., Seita J., Inlay M.A., Weiskopf K., Miyanishi M., Weissman I.L., et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA 2013, 110:11103-11108.
56. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
57. Zitvogel L., Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012, 1:1223-1225.
58. Terme M., Ullrich E., Aymeric L., Meinhardt K., Coudert J.D., Desbois M., Ghiringhelli F., Viaud S., Ryffel B., Yagita H., et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res 2012, 72:2757-2767.
59. Benson D.M., Bakan C.E., Mishra A., Hofmeister C.C., Efebera Y., Becknell B., Baiocchi R.A., Zhang J., Yu J., Smith M.K., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma. Blood 2010, 116:2286-2294.
60. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
61. Westin J.R., Chu F., Zhang M., Fayad L.E., Kwak L.W., Fowler N., Romaguera J., Hagemeister F., Fanale M., Samaniego F., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014, 15:69-77.